Omada Health hikes 2026 outlook after ‘strongest quarter ever’ in Q3
Omada Health reported record Q3 2026 results with $91M revenue (up 34% YoY), $7M net income, and 76% GAAP gross margin. It raised 2026 revenue outlook to $344M-$346M and adjusted EBITDA to $32M-$34M, citing strong member retention and growth in diabetes/hypertension programs. Stock dropped 19% post-earnings due to Q4 outlook concerns.
How this was made
The 30-second read
Why it matters
The earnings beat and guidance raise are offset by a 19% share decline due to concerns over Q4 enrollment seasonality, creating a short‑term trading opportunity.
Market read
Omada Health’s earnings and guidance revision directly affect its stock price and may influence sentiment toward the broader digital health sector.
What to watch
Strong gross margins (76% GAAP) and expanding PBM partnerships may provide longer‑term upside despite near‑term enrollment slowdown.
Background
Omada Health, a virtual chronic‑care provider that went public in June 2025, announced its strongest quarter ever and updated its 2026 outlook.
Market effects
Highlights growth and margin potential in digital chronic‑care platforms, but underscores enrollment seasonality risks for the sector.
U.S. digital health stocks may see short‑term volatility as investors reassess Q4 seasonality.
Limited to U.S. health‑tech investors; no broader macro impact.
Counterpoint
The raised full‑year revenue and EBITDA outlook could support a bounce if the market overreacts to seasonal concerns.
Key entities
- ExecutiveSean Duffy
CEO and co‑founder who presented the earnings results.
- ExecutiveWei‑Li Shao
President (incoming CEO) who discussed partnership expansions and AI initiatives.
